180 related articles for article (PubMed ID: 21987172)
1. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
Shiota M; Zoubeidi A; Kumano M; Beraldi E; Naito S; Nelson CC; Sorensen PH; Gleave ME
Mol Cancer Res; 2011 Dec; 9(12):1755-66. PubMed ID: 21987172
[TBL] [Abstract][Full Text] [Related]
2. GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.
Li N; Zoubeidi A; Beraldi E; Gleave ME
Oncogene; 2013 Apr; 32(15):1933-42. PubMed ID: 22689054
[TBL] [Abstract][Full Text] [Related]
3. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
4. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of clusterin expression increases the in vitro sensitivity of human prostate cancer cells to paclitaxel.
Chun YJ
J Toxicol Environ Health A; 2014; 77(22-24):1443-50. PubMed ID: 25343293
[TBL] [Abstract][Full Text] [Related]
6. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.
Al Nakouzi N; Wang CK; Beraldi E; Jager W; Ettinger S; Fazli L; Nappi L; Bishop J; Zhang F; Chauchereau A; Loriot Y; Gleave M
EMBO Mol Med; 2016 Jul; 8(7):761-78. PubMed ID: 27198502
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
8. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
9. Nuclear clusterin accumulation during heat shock response: implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells.
Caccamo AE; Desenzani S; Belloni L; Borghetti AF; Bettuzzi S
J Cell Physiol; 2006 Apr; 207(1):208-19. PubMed ID: 16331665
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer.
Ma X; Zou L; Li X; Chen Z; Lin Q; Wu X
Biomed Pharmacother; 2018 Mar; 99():445-450. PubMed ID: 29665645
[TBL] [Abstract][Full Text] [Related]
11. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth.
Takeuchi A; Shiota M; Beraldi E; Thaper D; Takahara K; Ibuki N; Pollak M; Cox ME; Naito S; Gleave ME; Zoubeidi A
Mol Cell Endocrinol; 2014 Mar; 384(1-2):117-25. PubMed ID: 24491388
[TBL] [Abstract][Full Text] [Related]
13. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
Lourda M; Trougakos IP; Gonos ES
Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323
[TBL] [Abstract][Full Text] [Related]
14. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis.
Mo Q; Zhang Y; Jin X; Gao Y; Wu Y; Hao X; Gao Q; Chen P
Tumour Biol; 2016 Nov; 37(11):14745-14755. PubMed ID: 27629142
[TBL] [Abstract][Full Text] [Related]
15. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line.
Tian B; Liu J; Liu B; Dong Y; Liu J; Song Y; Sun Z
J Cell Physiol; 2011 Dec; 226(12):3433-41. PubMed ID: 21344396
[TBL] [Abstract][Full Text] [Related]
16. Clusterin mediates TRAIL resistance in prostate tumor cells.
Sallman DA; Chen X; Zhong B; Gilvary DL; Zhou J; Wei S; Djeu JY
Mol Cancer Ther; 2007 Nov; 6(11):2938-47. PubMed ID: 18025278
[TBL] [Abstract][Full Text] [Related]
17. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
18. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism.
Xu S; Wang T; Song W; Jiang T; Zhang F; Yin Y; Jiang SW; Wu K; Yu Z; Wang C; Chen K
Sci Rep; 2015 Aug; 5():13528. PubMed ID: 26314494
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia inducible factor-1α directly regulates nuclear clusterin transcription by interacting with hypoxia response elements in the clusterin promoter.
Park J; Park SY; Shin E; Lee SH; Kim YS; Lee DH; Roh GS; Kim HJ; Kang SS; Cho GJ; Jeong BY; Kim H; Choi WS
Mol Cells; 2014 Feb; 37(2):178-86. PubMed ID: 24599003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
